Clinical Study With Medicine Sensitive Experiment In Non-Small Cell Lung Cancer In Vitro

BACKGROUD The study of some scholar showed that post-operative adjuvant chemotherapy of non-small cell lung cancer(NSCLC)patients with 5-year survival rate increased by 5%.The chemotherapy drugs of second generation further enhance the survival rate of the stageⅠb～Ⅲa of the patients with NSCLC.The current study that how to choose chemotherapy drugs and to optimize to identify individual chemotherapy to maximize the efficacy and reduce the side effects before chemotherapy is a difficult and hot issue.In vitro cancer,is now considered to avoid anti-cancer drug poor selectivity and reduce the role of chemotherapy blindness of the important methods.OBJECTIVE Through non-small cell lung cancer cells in vitro generation of the original culture,its commonly used chemotherapy drug susceptibility testing on different chemotherapy drugs and chemotherapy sensitivity difference between an attempt to screen out the best chemotherapy or combination chemotherapy,according to the best regimen of chemotherapy,the 5-year survival rate was observed,and with conventional chemotherapy and non-chemotherapy group compared in the experimental sensitivity of clinical application.METHODS Retrospective analysis in our hospital from January 1,2000 to December 31,2001,were diagnosed as postoperative pathologyⅠb-Ⅲa period of 155 cases of NSCLC patients,divided into postoperative sensitivity test group,conventional chemotherapy group,and non-chemotherapy group. Conventional chemotherapy group of patients receiving vinorelbine or gemcitabine and cisplatin,such as chemotherapy,once every four weeks,a total of 3-4 cycles.Susceptibility of the experimental group MTT assay measured in 40 patients with non-small cell lung cancer tumor specimens commonly used chemotherapy drug commonly used combination chemotherapy and the sensitivity or resistance,and carry on the chemotherapy according to results of the patients.Statistics and compare the overall survival rate of 1,3,5 and 1,3,5-year survival period.RESULTS The survival time of the postoperative sensitivity test group is 5-60 months and the median survival time was 55 months,the survival time of the conventional chemotherapy group is 4-60 months,the median survival time was 45 months,the survival time of non-chemotherapy group was 3-60 months,the median survival time was 34 months;the 1,3,5-year survival rates of postoperative sensitivity test group were 85%,67.5%,45%,the conventional chemotherapy group's 1,3,5-year survival rates were 80.3%,63.6%,34.8%,the 1,3,5-year survival rates of non-chemotherapy group were 72.5%,49%,23.5%. There were significant difference in 1,3,5-year survival rate among the postoperative sensitivity test group,the conventional chemotherapy group and the non-chemotherapy group(p=0.032).Of whichⅠa-PhaseⅡwith 1,3,5-year survival rates were:Group sensitivity 90%,70%,50%,the conventional chemotherapy group was 76.5%,52.9%,47.1%, non-chemotherapy group was 71.4%,50%,35.7%,There were not significant difference in 1,3,5-year survival rate among the postoperative sensitivity test group,the conventional chemotherapy group and the non-chemotherapy group (P＞0.05),patients withⅢA 1,3,5-year survival rates were:sensitivity group, 83.3%,66.7%,43.3%,of conventional chemotherapy group was 81.6%,67.3%, 30.6%,non-chemotherapy group was 70.3%,48.6%,16.7%,There were not significant difference in 1,3-year survival rate among the postoperative sensitivity test group,the conventional chemotherapy group and the non-chemotherapy group(P＞0.05),there was significant difference of the 5-year survival rate among the three groups(P＜0.05).CONCLUSION For patients with early stage lung cancer,chemosensivity test guidance chemotherapy failed to improve survival rate compared with conventional chemotherapy.ForⅢA patients,drug sensitivity tests guidance chemotherapy can further improve the 5-year survival rate compared with conventional chemotherapy group.It is worth further exploration.MTT colorimetric assay is a feasible method to screen drugs of the guidingⅢA lung cancer patients.